Table 5.
Clinical characteristics of patients at the time of diagnosis with or without ESRD development during the follow-up period.
| Patients with ESRD during follow-up periodn = 17 | Patients without ESRD during follow-up periodn = 75 | p-value* | |
|---|---|---|---|
| Sex % men | 10 (58.8) | 42 (56) | 0.83 |
| Age at diagnosis | 40 (17–51) | 18 (12–36) | 0.035 |
| Follow-up period (years) | 1.6 (0.66–3.73) | 1.5 (0.7–3.5) | 0.83 |
| Non-visible hematuria, present | 13 (76.5) | 44 (58.6) | 0.17 |
| Visible hematuria, present | 3 (17.6) | 15 (20) | 0.82 |
| Nephrotic syndrome, present | 12 (70.6) | 36 (48) | 0.75 |
| Renal impairment, present | 10 (58.8) | 27 (36) | 0.08 |
| Renal failure, present | 5 (29.4) | 4 (5.3) | 0.002 |
| Sclerosis on light microscopy (%) | 27 (7–53) | 1.6 (0–18.3) | 0.004 |
| Crescent on light microscopy (%) | 0 (0–17.33) | 0 (0–7.08) | 0.78 |
| Serum C3, g/L | 0.78 (0.58–1.27) | 0.87 (0.41–1.2) | 0.8 |
| Serum C4, g/L | 0.24 (0.19–0.39) | 0.28 (0.22–0.36) | 0.71 |
| sC5b-9, ng/ml | 350 (234–615) | 421 (272–725) | 0.25 |
| Decreased C3, present | 10 (58.8) | 42 (56) | 0.8 |
| Decreased C3 with normal C4, present | 9 (52.9) | 32 (42.6) | 0.92 |
| Elevated sC5b-9, present | 10 (62.5) | 55 (73.3) | 0.23 |
| Classical pathway activity, CH50/ml | 48 (30.5–66.5) | 43 (21–60) | 0.21 |
| Alternative pathway activity, % | 76 (21–91) | 38 (1–83) | 0.08 |
| Serum FHR-5, mg/L | 1.96 (1.69–2.25) | 1.69 (1.35–2.34) | 0.18 |
| Patients with CFHR5 variations | 0 (0) | 13 (17.33) | 0.06 |
Data presented are: number (%) or median (interquartile range).
*Group comparisons were made with Mann–Whitney U test or χ2 test.
ESRD, end-stage renal disease; FHR-5, Factor H-related protein 5.
p-values < 0.05 are shown in bold.